References
- Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmunity Reviews 2005; 4: 162–70
- Sritangratanakul S, Nuchprayoon S, Nuchprayoon I. Pneumocystis pneumonia: an update. J Med Assoc Thai 2004; 87(Suppl 2)309–17
- Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Practice and Research Clinical Rheumatology 2003; 17: 345–63
- Bakhel M, Tleyjeh I, Matteson E.L, Osmon D.R. Infectious compilications of tumour necrosis factor-α antagonists. International Journal of Dermatology 2005; 44: 443–8
- Velayos F, Sandborn W.J. Pneumocystis carinii pneumonia during maintenance anti-tumour necrosis factor-α therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004; 10: 657–60
- Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 2002; 41: 951–2
- Chen W, Havell EA, Harmsen AG. Importance of endogenous tumour necrosis factor-alpha and gamma interferon in host resistance against Pneunocystis carinii infection. Infection and Immunity 1992; 4: 1279–1284
- Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti-tumour necrosis factor-alpha monoclonal antibody,and concomitant standard anti-rheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563–71
- www.fda.gov/cder/present/DIA2004/Tauber.ppt.
- Krebs S, Gibbons RB. Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia. Mil Med 1996; 161: 58–60